Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Retained Earnings (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Retained Earnings for 15 consecutive years, with -$660.8 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 177.41% year-over-year to -$660.8 million; the TTM value through Mar 2026 reached -$660.8 million, down 177.41%, while the annual FY2025 figure was -$561.7 million, 277.18% down from the prior year.
  • Retained Earnings hit -$660.8 million in Q1 2026 for Agios Pharmaceuticals, down from -$561.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$52.4 million in Q3 2024 and bottomed at -$1.0 billion in Q2 2024.
  • Average Retained Earnings over 5 years is -$520.2 million, with a median of -$507.1 million recorded in 2022.
  • Year-over-year, Retained Earnings tumbled 1181.15% in 2022 and then skyrocketed 92.79% in 2024.
  • Agios Pharmaceuticals' Retained Earnings stood at -$470.6 million in 2022, then crashed by 74.82% to -$822.6 million in 2023, then soared by 81.9% to -$148.9 million in 2024, then crashed by 277.18% to -$561.7 million in 2025, then fell by 17.64% to -$660.8 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$660.8 million, -$561.7 million, and -$453.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.